Table 1. Baseline demographic, alcohol use, and smoking variables.

	Placebo (n = 38)	Varenicline (n = 39)
Age (years)	32.61 (10.21)	34.85 (11.17)
Sex (% male)	64%	67%
Race
White	23 (64%)	27 (73%)
Other	13 (36 %)	8 (22%)
Marital status
Not married	28 (74%)	34 (89%)
Married	10 (26%)	5 (13%)
Alcohol Use
Disorder
Yes	24 (63%)	21 (54%)
No	14 (37%)	18 (46%)
Alcohol use
AUDIT	16.50 (5.71)	14.87 (4.92)
Drinks/week	26.87 (21.70)	28.63 (17.11)
Drinking episodes/week	4.81 (1.75)	4.60 (1.75)
% heavy drinking days	0.54 (0.36)	0.58 (0.33)
Smoking status
Smokers	18 (47%)	21 (54%)
Nonsmokers	20 (53%)	18 (46%)
Smoking
FTND	3.75 (2.41)	4.53 (2.67)
Cig/day	10.46 (8.36)	11.91 (8.19)

Note. Quantity/frequency measures of alcohol use and smoking are based on timeline follow-backs assessing patterns of use four weeks before starting medication. Alcohol Use Disorder indicates number of participants who met criteria for any alcohol use disorder on the SCID-I during the 6 months before intake. AUDIT is the Alcohol Use Disorder Identification Test. FTND is the Fagerström Test of Nicotine Dependence. For smoking variables, reported means and t-test comparisons are for smokers in each group. Chi square and t-test analyses found no significant differences between medication groups.